James M. Hoffman, Pharm.D., M.S., B.C.P.S. is an Associate Member in Pharmaceutical Sciences and the Medication Outcomes & Safety Officer at St. Jude Children's Research Hospital. He is also an associate professor at the University of Tennessee College of Pharmacy. He earned both his undergraduate and doctoral degree from the Philadelphia College of Pharmacy at the University of the Sciences in Philadelphia. He completed a M.S. degree at the University of Wisconsin-Madison, and training at the University of Wisconsin Hospital and Clinics. His primary interests include medication safety, clinical decision support, and the clinical implementation of pharmacogenetics.
PG4KDS: A model for the clinical implementation of pre-emptive pharmacogenetics
Article first published online: 11 MAR 2014
© 2014 Wiley Periodicals, Inc.
American Journal of Medical Genetics Part C: Seminars in Medical Genetics
Special Issue: Implementation of Genomic Medicine
Volume 166, Issue 1, pages 45–55, March 2014
How to Cite
2014. PG4KDS: A model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet Part C Semin Med Genet 166C:45–55., , , , , , , , , , , , , .
Conflict of Interest: Dr. Mary V. Relling and Dr. William E. Evans receive royalties from licensing TPMT genotyping, Prometheus Labs.
* Correspondence to: James M. Hoffman, St. Jude Children's Research Hospital, Pharmaceutical Sciences Department, 262 Danny Thomas Place MS #150, Memphis, TN 38105. E-mail: firstname.lastname@example.org
- Issue published online: 18 MAR 2014
- Article first published online: 11 MAR 2014
- NCI. Grant Numbers: CA 36401, CA 21765
- NIH/NIGMS Pharmacogenomics Research Network. Grant Numbers: U01 GM92666, UO1 HL105918
- The American Lebanese Syrian Associated Charities (ALSAC)
This article has been cited by:
- 1Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy, Blood Reviews, 2015,, , , , , ,
- 2Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers, Annual Review of Pharmacology and Toxicology, 2015, 55, 1, 89, , , , , , , , , ,
- 3Combining genetic and nongenetic biomarkers to realize the promise of pharmacogenomics for inflammatory diseases, Pharmacogenomics, 2014, 15, 15, 1931, ,
- 5Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia, Frontiers of Medicine, 2014,,
- 6Pharmacogenetic biomarkers for predicting drug response, Expert Review of Molecular Diagnostics, 2014, 14, 6, 723, , ,
- 7Pilot study: incorporation of pharmacogenetic testing in medication therapy management services, Pharmacogenomics, 2014, 15, 14, 1729, , , , , ,